CRYAB (crystallin alpha B) is a small heat shock protein functioning primarily as a molecular chaperone that prevents protein aggregation under stress conditions 1. Beyond its canonical role in lens transparency, CRYAB stabilizes various proteins including FTH1 and ATP6V1A through proteasome-dependent mechanisms, while also localizing to mitochondria where it exhibits antiapoptotic activity 23. CRYAB regulates protein phase separation into condensates, with phosphorylation at serine 59 altering condensate fluidity and promoting aggregation 4. Dysfunction of CRYAB contributes to multiple diseases. Mutations cause myofibrillar myopathy (p.Gly154Ser) and hereditary optic atrophy (p.Glu105Lys) through impaired chaperone activity and increased apoptosis 13. In ischemic cardiomyopathy, elevated CRYAB phosphorylation drives condensatopathy and ventricular remodeling 4. Conversely, CRYAB overexpression promotes pathological processes in cancer, enhancing colorectal cancer stem cell properties via Wnt/Ξ²-catenin signaling and gastric cancer angiogenesis and metastasis 56. Additionally, molecular mimicry between CRYAB and Epstein-Barr virus EBNA1 generates cross-reactive antibodies associated with multiple sclerosis risk 7. These findings identify CRYAB phosphorylation and protein condensate dynamics as therapeutic targets for cardiomyopathy and suggest CRYAB inhibition may benefit certain cancers.